Seeking Alpha

Wedbush initiates coverage on NPS Pharmaceuticals (NPSP) at Outperform with a lofty $14 price...

Wedbush initiates coverage on NPS Pharmaceuticals (NPSP) at Outperform with a lofty $14 price target. Analysts with the firm expect that not only will Gattex win FDA approval, but that the cancer drug will also deliver $252M in global revenue in 2015.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)